OCT Clinical Trials — The Leading CRO in Eastern Europe

The Leading CRO in Eastern Europe

Since 2005, we have conducted hundreds of clinical trials in Russia and all of Eastern Europe. Our full range of CRO services has helped sponsors worldwide in offshoring their clinical trials and bringing their innovative treatments to market.

Thorough local expertise

• 14+ years’ experience facilitating clinical trials in Russia and Europe
• Risk-management approach
• 300+ clinical studies in portfolio
• Team of 200+ clinical operations professionals

Global sponsors

• Extensive project portfolio with sponsors from EU, US, CIS and Asia
• Successfully passed more than 60 audits by sponsors with no significant findings

Record-setting patient enrollment

• Access to the network of 1600+ leading scientific sites
• Extensive experience in fast enrollment of patients with different indications
• Patient engagement solutions
• CRO site management services

Quality

• FDA/EMA acceptable data
• Compliance with the international standards (ICH GCP), local regulatory requirements and internal SOPs

News

all news

Sep

OCT Clinical Appoints Maxime Stevens as chief Strategy and Development Officer

OCT Clinical today announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer. In her role, she is responsible for establishing business development vision, creating roadmaps for global expansion.

read

[Webinar]: Choosing the Right CRO: Global or Local? Here’s What to Consider

Sign up now for a free webinar from OCT, the leading CRO in Eastern Europe and an experienced operator from the Baltic to Bulgaria. Irina Petrova MD, director of clinical operations, will guide you by sharing insights.

read

Sep

Aug

Why Russia is among the hottest clinical trials destinations

Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, elaborated on why foreign sponsors choose Russia as a clinical research arena in her article for Applied Clinical Trials.

read

OCT APPLIED FOR REGULATORY APPROVAL FOR A STUDY IN PATIENTS WITH INFECTION DISEASES

This is a multicenter, randomized, double-blind, placebo-controlled study, which is aimed to evaluate the efficacy and safety of a drug for treatment of acute viral respiratory infections and flu in adults vs. placebo.

read